Pipeline
We start with the animal, not the ingredient.
These are development programmes. Nothing on this page is available to buy, and nothing here claims a result we have not yet produced.
01 · How we work
These are the fields we investigate. Which one a programme reaches for depends entirely on what the condition needs — and none of them is a finished product, and none of them works alone.
Short chains of amino acids — the same building blocks proteins are made of — either found in nature or designed from scratch.
We investigate them for their potential to interact selectively with biological targets, including in infection, bacterial biofilm, inflammation and tissue recovery.
investigate
Long chains of sugars, natural or engineered. They can act as the therapy, or as the structure that carries one.
We explore their potential roles in bioadhesion, tissue protection, wound support, formulation structure and controlled delivery.
explore
A gas with distinctive physicochemical and biological properties, and a long history in veterinary use that has rarely been examined rigorously.
We assess where those properties may contribute to local veterinary care. Concepts are evaluated through evidence-based formulation, safety assessment and biological validation appropriate to the intended species and use.
assess
Carriers built at the scale of billionths of a metre — small enough to travel with a compound and release it where it is needed.
We investigate how active compounds can be protected, solubilised, targeted or delivered more effectively, and how nanoscale systems may improve stability, bioavailability, tissue interaction and local performance while supporting carefully controlled dosing.
investigate
Systems that control when, where and how an active compound is released.
We develop them to extend local residence time, improve adherence, protect sensitive ingredients, reduce dosing frequency and enhance clinical performance.
develop
Nature, biological pathways and traditional knowledge — put through evidence rather than taken on faith.
We investigate them systematically to identify mechanisms that may improve the standard of care. Scientific evidence guides the first nature-inspired formulations, which are then evaluated and optimised for efficacy, safety, stability and manufacturability.
investigate
Public and proprietary platforms that find patterns in biological data no person could hold in their head at once.
We use them, alongside computational modelling and molecular design, to identify opportunities and to optimise active compounds and formulations for efficacy, selectivity and safety.
use
Innovation beyond the active compound: the bottle, the applicator, the tool someone actually holds at five in the morning in a milking parlour.
We engineer complete product ecosystems that may include formulation technology, delivery systems, packaging and supporting tools, designed to improve the experience of veterinary professionals and animal caregivers.
engineer
02 · The test
Every computational prediction must ultimately be tested against biological reality.
03 · What we are developing
Our approach begins with a clear clinical need and a careful evaluation of the work required.
Disease and mechanism evaluation
We define the clinical problem, establish what is actually known about it, and identify the biological mechanism a therapy would have to reach.
Selection and design of components
We choose or design the active components — from the eight fields above — that could act on that mechanism.
Building the formulation
We turn components into a formulation: how it holds together, how it is delivered, how it stays where it is put.
In vitro testing
Laboratory studies to assess safety, mechanism of action and therapeutic potential. Results feed back into the formulation.
Efficacy and safety
The studies that establish whether it works and whether it is safe, in the species it is intended for.
Registration
Submission to the veterinary authorities of each market, and the approval that permits sale.
04 · Priority area one
To be disclosed soon.
05 · Priority area two
To be disclosed soon.
06 · Programme information
We collaborate with scientists, veterinarians, universities and research centres around the world. If your expertise touches infections and bacterial biofilm, inflammation and tissue recovery, nature-inspired therapeutics, computational discovery or advanced formulation, we would like to hear from you.
The pipeline has room in it that nothing occupies yet. We would rather show the gap than pretend it is full.
Talk to us about collaboration [email protected]